Prevalence and Incidence of Immune Thrombocytopenia in Patients With Prostate Cancer

Vontela, Namratha; Kövesdy, Csaba P.; Latif, ZA; Lane, R.D. Helen W.; Weir, Alva

doi:10.1016/j.amjms.2018.05.003

Cited by 1 publication

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although immunosuppressive treatments can increase the risk of for example, skin cancer, 43 this observation could suggest that solid cancer and ITP can be coincidental and may not be causally linked. 44,45 Cardiovascular csHR for death was 1.49 for pITP versus 2.78 for sITP. A comparable study found a 1.5-fold increased risk of death from cardiovascular disease 18 and cardiovascular thromboembolic disease generally occurs more frequently in patients with ITP.…”

Section: Discussionmentioning

confidence: 94%

“…Death from solid cancer was also relatively more frequent in patients, but with smaller differences between patients and the general population than other causes of death. Although immunosuppressive treatments can increase the risk of for example, skin cancer, 43 this observation could suggest that solid cancer and ITP can be co‐incidental and may not be causally linked 44,45 …”

Section: Discussionmentioning

confidence: 99%

“…Although immunosuppressive treatments can increase the risk of for example, skin cancer, 43 this observation could suggest that solid cancer and ITP can be co‐incidental and may not be causally linked. 44 , 45 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Survival in adult patients with chronic primary and secondary immune thrombocytopenia: A population‐based study

et al. 2023

View full text Add to dashboard Cite

Background Few studies have investigated long‐term survival in patients with primary immune thrombocytopenia (pITP). Further, changes in prognosis over the past decades and prognosis of secondary immune thrombocytopenia (sITP) are largely unstudied. Our objectives were to study comorbidity‐adjusted prognostic changes and causes of death in chronic pITP and sITP patients. Study Design/Methods Using nationwide Danish health registries 1980–2016, we identified 1762 patients with chronic pITP (median age 58 (IQR, 37–73) years) and 128 with chronic sITP (median age 59 (IQR, 40–73) years). Patients were age‐sex‐matched to 74,781 general population comparators. Comorbidity was assessed using Charlson Comorbidity Index (CCI). Results Overall median survival was reduced by 5.1 years (95% CI, 0.7–9.4) (p < .001) for pITP and 11.1 years (95% CI, 5.8–16.4) (p < .001) for sITP. 5‐year survival increased from 69% (95% CI, 59–78) in 1980–89 to 80% (95% CI, 75–83) in 2010–16 for pITP, and decreased from 100% (95% CI, 89–98) to 64% (95% CI, 87–91) for sITP. However, numbers were small for sITP. 5‐year survival for pITP with high CCI was 41% (95% CI, 32–49), and 85% (95% CI, 83–87) for low CCI. Bleeding, infection and hematological cancer were relatively frequent causes of death with adjusted subhazard ratios of 3.25 (95% CI, 2.33–4.52), 1.53 (95% CI, 1.08–2.16) and 2.16 (95% CI, 1.12–4.16) in pITP respectively, and 10.52 (95% CI, 1.43–77.36) for hematological cancer in sITP. Conclusions Long‐term survival is reduced in chronic ITP but seems to be improving. Comorbidity and sITP are associated with a poor prognosis.

show abstract